Results 221 to 230 of about 23,970 (278)

Carbonic Anhydrase Inhibitors

ChemInform, 2002
AbstractFor Abstract see ChemInform Abstract in Full Text.
SCOZZAFAVA, ANDREA, SUPURAN, CLAUDIU TRANDAFIR, A. CASINI   +2 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Novel Carbonic Anhydrase Inhibitors

Future Medicinal Chemistry, 2021
Abstract
openaire   +3 more sources

Topical carbonic anhydrase inhibitors

Journal of Medicinal Chemistry, 1984
Ethoxzolamide and several derivatives (1-6) were synthesized and evaluated for carbonic anhydrase inhibition (CAI), solubility, pKa, distribution, and corneal permeability. The 6-hydroxy (5) and, particularly, the 6-chloro (6) analogues have the best combination of properties for penetrating the site of action and reducing intraocular pressure.
R D, Schoenwald, M G, Eller, J A, Dixson, C F, Barfknecht   +3 more
openaire   +2 more sources

Hydroxyurea is a carbonic anhydrase inhibitor

Bioorganic & Medicinal Chemistry, 2003
The interaction of hydroxyurea with the cytosolic isozymes of carbonic anhydrase (CA), hCA I and hCA II has been investigated by means of kinetic and spectroscopic techniques. Hydroxyurea acts as a weak, non-competitive inhibitor of both isozymes, for the 4-nitrophenyl acetate esterase activity, with inhibition constants around 0.1 mM for both isozymes.
SCOZZAFAVA, ANDREA, SUPURAN, CLAUDIU TRANDAFIR   +1 more
openaire   +3 more sources

Sulfonylmethanesulfonamide inhibitors of carbonic anhydrase

Journal of Medicinal Chemistry, 1993
A series of sulfonylmethanesulfonamide derivatives is described, which are inhibitors of carbonic anhydrase (CA). The most potent of these is the racemic fluoro sulfone 9, which inhibits carbon dioxide hydration catalyzed by human CA II (CA-II) with an IC50 of 3 nM.
T H, Scholz, J M, Sondey, W C, Randall, H, Schwam, W J, Thompson, P J, Mallorga, M F, Sugrue, S L, Graham   +7 more
openaire   +2 more sources

Topical carbonic anhydrase inhibitors

Current Opinion in Ophthalmology, 1997
Dorzolamide, a topically active carbonic anhydrase inhibitor, is an effective new glaucoma medication that creates a decrease in intraocular pressure similar to that produced by beta-blockers. When beta-blockers are contraindicated, dorzolamide may be used as a first-line therapy.
D M, Talluto, T B, Wyse, T, Krupin
openaire   +2 more sources

Carbonic anhydrase inhibitors

Bioorganic & Medicinal Chemistry Letters, 2010
Carbonic anhydrases (CAs, EC 4.2.1.1) are widespread enzymes in all organisms, catalyzing CO2 hydration to bicarbonate and protons. Their inhibition is exploited clinically for decades for various classes of diuretics and systemically acting antiglaucoma agents.
openaire   +2 more sources

Antiobesity Carbonic Anhydrase Inhibitors

Current Topics in Medicinal Chemistry, 2007
Few pharmacological approaches for the treatment of obesity exist at this time, and most of them are unsatisfactory, whereas this disease is widespread both in the developed and developing world. Novel effective approaches are needed for the development of antiobesity agents possessing different mechanisms of action.
G. D. Simone, SUPURAN, CLAUDIU TRANDAFIR
openaire   +3 more sources

Carborane‐Based Carbonic Anhydrase Inhibitors

Angewandte Chemie International Edition, 2013
CA inhibitors: Human carbonic anhydrases (CAs) are diagnostic and therapeutic targets. Various carborane cages are shown to act as active-site-directed inhibitors, and substitution with a sulfamide group and other substituents leads to compounds with high selectivity towards the cancer-specific isozyme IX.
Brynda, J. (Jiří), Mader, P. (Pavel), Šícha, V. (Václav), Fábry, M. (Milan), Poncová, K. (Kristýna), Bakardjiev, M. (Mario), Grüner, B. (Bohumír), Cígler, P. (Petr), Řezáčová, P. (Pavlína)   +8 more
openaire   +3 more sources

Safety of carbonic anhydrase inhibitors

Expert Opinion on Drug Safety, 2014
Carbonic anhydrase (CA) inhibitors have an impressive safety record despite the multiple functions that CA isozymes serve because they are not fully inhibited with most dosing. While reducing the targeted CA-dependent process sufficiently for disease control, residual activity and uncatalyzed rates in combination with compensations are adequate to ...
openaire   +2 more sources